GURUFOCUS.COM » STOCK LIST » Real Estate » REITs » BioMed Realty Trust Inc (NYSE:BMR) » Definitions » Debt-to-EBITDA

BioMed Realty Trust (BioMed Realty Trust) Debt-to-EBITDA : 6.53 (As of Sep. 2015)


View and export this data going back to . Start your Free Trial

What is BioMed Realty Trust Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

BioMed Realty Trust's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2015 was $463.0 Mil. BioMed Realty Trust's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2015 was $2,532.2 Mil. BioMed Realty Trust's annualized EBITDA for the quarter that ended in Sep. 2015 was $458.9 Mil. BioMed Realty Trust's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2015 was 6.53.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for BioMed Realty Trust's Debt-to-EBITDA or its related term are showing as below:

BMR's Debt-to-EBITDA is not ranked *
in the REITs industry.
Industry Median: 7.18
* Ranked among companies with meaningful Debt-to-EBITDA only.

BioMed Realty Trust Debt-to-EBITDA Historical Data

The historical data trend for BioMed Realty Trust's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioMed Realty Trust Debt-to-EBITDA Chart

BioMed Realty Trust Annual Data
Trend Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.11 6.99 6.94 7.91 5.05

BioMed Realty Trust Quarterly Data
Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.88 3.11 6.33 6.14 6.53

Competitive Comparison of BioMed Realty Trust's Debt-to-EBITDA

For the REIT - Office subindustry, BioMed Realty Trust's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioMed Realty Trust's Debt-to-EBITDA Distribution in the REITs Industry

For the REITs industry and Real Estate sector, BioMed Realty Trust's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where BioMed Realty Trust's Debt-to-EBITDA falls into.



BioMed Realty Trust Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

BioMed Realty Trust's Debt-to-EBITDA for the fiscal year that ended in Dec. 2014 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(84 + 2635.664) / 538.537
=5.05

BioMed Realty Trust's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2015 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(463 + 2532.169) / 458.896
=6.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2015) EBITDA data.


BioMed Realty Trust  (NYSE:BMR) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


BioMed Realty Trust Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of BioMed Realty Trust's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


BioMed Realty Trust (BioMed Realty Trust) Business Description

Traded in Other Exchanges
N/A
Address
BioMed Realty Trust Inc, a Maryland corporation was formed on April 30, 2004 and commenced operations on August 11, 2004, after completing its initial public offering. The Company operates as a self-administered and self-managed real estate investment trust focused on acquiring, developing, owning, leasing and managing laboratory and office space for the life science industry mainly through its subsidiary, BioMed Realty, L.P., a Maryland limited partnership Its tenants mainly include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. The Company's properties are generally located in markets with well established reputations as centers for scientific research, including Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/ New Jersey. The Company faces competition from various entities for investment opportunities in properties for life science tenants, including other REITs, such as health care REITs and suburban office property REITs, pension funds, insurance companies, investment funds and companies, partnerships, and developers. The Company's properties are subject to various laws, ordinances and regulations, including regulations relating to common areas.
Executives
Daniel Bradbury director BIOBRIT, LLC, 2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037
Brody William R Md Phd director MEDTRONIC, INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604
Janice L. Sears director 1100 PARK PLACE, SUITE 200, SAN MATEO CA 94403
Alan D Gold director, officer: Chairman, President and CEO 17140 BERNARDO CENTER DRIVE, SUITE 195, SAN DIEGO CA 92128
Gary A Kreitzer director, officer: Exec VP and Assistant Sec 17140 BERNARDO CENTER DRIVE, SUITE 195, SAN DIEGO CA 92128
Margaret Faye Wilson director 12836 LUNADA PLACE, SAN DIEGO CA 92128
Griffin R Kent Jr officer: President and COO 5950 SHERRY LANE, SUITE 700, DALLAS TX 75225
Richard I Gilchrist director 5950 SHERRY LANE, SUITE 700, DALLAS TX 75225